Form 4: Theodore R. Samuels II Reports Acquisition of Deferred Share Units in Bristol-Myers Squibb Co.

Director Theodore R. Samuels II reports acquisition of deferred share units convertible to common stock in Bristol-Myers Squibb Co.

Summary

• Theodore R. Samuels II, a director of Bristol-Myers Squibb Co. (BMY), reported the acquisition of 819.807 deferred share units on March 31, 2025.
• These units will convert into shares of common stock upon settlement, which occurs when Samuels ceases to be a director or at a previously specified future date.
• The price of the deferred share units is $60.99.
• Following the reported transaction, Samuels beneficially owns 57,676.273 shares, including deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing indicating a director's compensation in the form of deferred share units.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which will occur when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of deferred share units by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.

Key Dates

Keywords

Form 4, Beneficial Ownership, Deferred Share Units, Director, Bristol-Myers Squibb, BMY, Samuels